Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) shot up 8.5% on Thursday . The company traded as high as $6.93 and last traded at $6.87, 836,111 shares were traded during mid-day trading. An increase of 12% from the average session volume of 747,409 shares. The stock had previously closed at $6.33.
A number of brokerages have recently weighed in on ALDX. Oppenheimer began coverage on Aldeyra Therapeutics in a research report on Tuesday, July 7th. They issued a “buy” rating and a $15.00 price objective on the stock. Laidlaw reiterated a “buy” rating and issued a $30.00 price objective on shares of Aldeyra Therapeutics in a research report on Tuesday, May 26th. Zacks Investment Research lowered Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 8th. Finally, Janney Montgomery Scott restated a “market perform” rating and set a $28.00 price target on shares of Aldeyra Therapeutics in a research report on Tuesday, May 26th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $21.75.
The company has a debt-to-equity ratio of 0.34, a quick ratio of 12.84 and a current ratio of 12.84. The company has a market capitalization of $204.66 million, a PE ratio of -3.23 and a beta of 2.11. The firm has a fifty day simple moving average of $5.07 and a 200 day simple moving average of $4.24.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.14. Research analysts expect that Aldeyra Therapeutics, Inc will post -1.51 EPS for the current fiscal year.
In related news, major shareholder Perceptive Advisors Llc acquired 3,200,000 shares of Aldeyra Therapeutics stock in a transaction on Thursday, July 9th. The stock was acquired at an average price of $4.25 per share, for a total transaction of $13,600,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 15.00% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Oxford Asset Management LLP purchased a new stake in Aldeyra Therapeutics during the 4th quarter worth approximately $84,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at $88,000. Spark Investment Management LLC purchased a new stake in Aldeyra Therapeutics in the 1st quarter worth about $40,000. Squarepoint Ops LLC purchased a new stake in Aldeyra Therapeutics in the 1st quarter worth about $75,000. Finally, Acadian Asset Management LLC increased its holdings in Aldeyra Therapeutics by 559.5% in the 1st quarter. Acadian Asset Management LLC now owns 33,098 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 28,079 shares during the last quarter. Institutional investors own 56.34% of the company’s stock.
About Aldeyra Therapeutics (NASDAQ:ALDX)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.